Abstract
Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant correlation between PSA response and overall survival was also noted. The regression analysis revealed PSA level to be predictive of overall survival. Conclusion: Enzalutamide was shown to be an effective and welltolerated therapeutic option in patients with metastatic castration-resistant prostate cancer progressing after docetaxel plus prednisone treatment.
| Lingua originale | English |
|---|---|
| pagine (da-a) | 1475-1480 |
| Numero di pagine | 6 |
| Rivista | Anticancer Research |
| Volume | 37 |
| Stato di pubblicazione | Published - 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cita questo
De Luca, R., Cicero, G., Dieli, F., & Dorangricchia, P. (2017). The clinical efficacy of enzalutamide in metastatic prostate cancer: Prospective single-center study. Anticancer Research, 37, 1475-1480.